A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.


Updates from The Motley Fool

Latest updates on United Therapeutics from Fool.com.  The Fool has written over 100 articles on United Therapeutics.
This Week in Biotech

An FDA approval, a mixed batch of clinical data, a welcome pipeline update, and an ongoing patent...

This Week in Biotech

Two FDA rulings and three late-stage clinical updates created some very large moves this week in ...



Stock Performance

View Interactive UTHR Charts
Sponsored by

Key Data Points

Primary metrics and data points about United Therapeutics.
Current Price: $139.13
Prev Close: $139.37
Open: $139.08
Bid: $123.85
Ask: $141.87
Day's Range: $137.63 - $141.36
52wk Range: $97.52 - $169.89
Volume: 427,834
Avg Vol 603,962
Market Cap: $6B
P/E (ttm): 9.14
EPS (ttm): $15.25
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about United Therapeutics.
CAPS Rating 4 out of 5
 
270 Outperform
17 Underperform
CAPS All Stars
 
74 Outperform
4 Underperform

How do you think United Therapeutics will perform against the market?



You pick for United Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Martine A. Rothblatt, CEO

85% Approve

Based on 41 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for United Therapeutics.

A biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers